^

Association details:

Evidence:

Evidence Level:
Sensitive: C4 – Case Studies
New
Title:
Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
Published date:
04/28/2021
Excerpt:
...52-year-old female patient with EGFR-mutated stage IV lung adenocarcinoma...first clinical evidence that the osimertinib and anlotinib-based regimen may be an effective therapy in overcoming resistance mediated by T790M-cis-C797S.
DOI:
https://doi.org/10.2147/OTT.S298655
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our